Skip to Main content Skip to Navigation
New interface
Journal articles

Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.

Alessandro Muzzi 1 Alessandro Brozzi 1 Laura Serino 1 Margherita Bodini 1 Raquel Abad 2 Dominique A Caugant 3 Maurizio Comanducci 1 Ana Paula Lemos 4 Maria Cecilia Gorla 4 Pavla Křížová 5 Claudia Mikula 6 Robert Mulhall 7 Michael Nissen 8 Hanna Nohynek 9 Maria João Simões 10 Anna Skoczyńska 11 Paola Stefanelli 12 Muhamed-Kheir Taha 13 Maija Toropainen 9 Georgina Tzanakaki 14 Kumaran Vadivelu-Pechai 15 Philip Watson 15 Julio A Vazquez 2 Gowrisankar Rajam 16 Rino Rappuoli 1 Ray Borrow 17 Duccio Medini 1, * 
Abstract : BACKGROUND: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. METHODS: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. RESULTS: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. CONCLUSIONS: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.
Complete list of metadata

Cited literature [40 references]  Display  Hide  Download
Contributor : Muhamed-Kheir TAHA Connect in order to contact the contributor
Submitted on : Sunday, February 10, 2019 - 5:17:37 PM
Last modification on : Thursday, April 7, 2022 - 10:10:25 AM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License




Alessandro Muzzi, Alessandro Brozzi, Laura Serino, Margherita Bodini, Raquel Abad, et al.. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.. Vaccine, 2019, 37 (7), pp.991-1000. ⟨10.1016/j.vaccine.2018.12.061⟩. ⟨pasteur-02013229⟩



Record views


Files downloads